IMRX Annual EBITDA
-$58.06 M
-$6.59 M-12.81%
31 December 2023
Summary:
As of January 23, 2025, IMRX annual earnings before interest, taxes, depreciation & amortization is -$58.06 million, with the most recent change of -$6.59 million (-12.81%) on December 31, 2023. During the last 3 years, it has fallen by -$41.06 million (-241.47%). IMRX annual EBITDA is now -691.01% below its all-time high of -$7.34 million, reached on December 31, 2019.IMRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMRX Quarterly EBITDA
-$15.18 M
-$362.50 K-2.45%
30 September 2024
Summary:
As of January 23, 2025, IMRX quarterly earnings before interest, taxes, depreciation & amortization is -$15.18 million, with the most recent change of -$362.50 thousand (-2.45%) on September 30, 2024. Over the past year, it has increased by +$50.30 thousand (+0.33%). IMRX quarterly EBITDA is now -370.78% below its all-time high of -$3.22 million, reached on March 31, 2020.IMRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMRX TTM EBITDA
-$73.81 M
-$1.34 M-1.84%
30 September 2024
Summary:
As of January 23, 2025, IMRX TTM earnings before interest, taxes, depreciation & amortization is -$73.81 million, with the most recent change of -$1.34 million (-1.84%) on September 30, 2024. Over the past year, it has dropped by -$2.73 million (-3.84%). IMRX TTM EBITDA is now -2189.52% below its all-time high of -$3.22 million, reached on March 31, 2020.IMRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.8% | +0.3% | -3.8% |
| 3 y3 years | -241.5% | -9.2% | -43.7% |
| 5 y5 years | -691.0% | -9.2% | -43.7% |
IMRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -72.2% | at low | -37.2% | +46.9% | -118.9% | at low |
| 5 y | 5-year | -691.0% | at low | -370.8% | +46.9% | -2189.5% | at low |
| alltime | all time | -691.0% | at low | -370.8% | +46.9% | -2189.5% | at low |
Immuneering EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$15.18 M(+2.4%) | -$73.81 M(+1.8%) |
| June 2024 | - | -$14.82 M(-2.7%) | -$72.48 M(+2.0%) |
| Mar 2024 | - | -$15.23 M(-46.7%) | -$71.08 M(+1.0%) |
| Dec 2023 | -$58.06 M(+12.8%) | -$28.59 M(+106.6%) | -$70.37 M(+26.4%) |
| Sept 2023 | - | -$13.84 M(+3.1%) | -$55.68 M(+1.3%) |
| June 2023 | - | -$13.42 M(-7.5%) | -$54.95 M(+3.3%) |
| Mar 2023 | - | -$14.52 M(+4.4%) | -$53.17 M(+3.5%) |
| Dec 2022 | -$51.47 M | -$13.90 M(+6.0%) | -$51.38 M(+5.8%) |
| Sept 2022 | - | -$13.11 M(+12.7%) | -$48.54 M(+10.5%) |
| June 2022 | - | -$11.64 M(-8.5%) | -$43.93 M(+9.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$12.73 M(+15.0%) | -$40.25 M(+19.3%) |
| Dec 2021 | -$33.73 M(+98.4%) | -$11.06 M(+30.1%) | -$33.73 M(+18.5%) |
| Sept 2021 | - | -$8.51 M(+6.9%) | -$28.47 M(+16.9%) |
| June 2021 | - | -$7.96 M(+28.3%) | -$24.35 M(+21.8%) |
| Mar 2021 | - | -$6.20 M(+6.9%) | -$19.98 M(+17.5%) |
| Dec 2020 | -$17.00 M(+131.6%) | -$5.80 M(+32.4%) | -$17.00 M(+51.8%) |
| Sept 2020 | - | -$4.38 M(+22.1%) | -$11.20 M(+64.3%) |
| June 2020 | - | -$3.59 M(+11.4%) | -$6.81 M(+111.4%) |
| Mar 2020 | - | -$3.22 M | -$3.22 M |
| Dec 2019 | -$7.34 M | - | - |
FAQ
- What is Immuneering annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Immuneering?
- What is Immuneering annual EBITDA year-on-year change?
- What is Immuneering quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Immuneering?
- What is Immuneering quarterly EBITDA year-on-year change?
- What is Immuneering TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Immuneering?
- What is Immuneering TTM EBITDA year-on-year change?
What is Immuneering annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of IMRX is -$58.06 M
What is the all time high annual EBITDA for Immuneering?
Immuneering all-time high annual earnings before interest, taxes, depreciation & amortization is -$7.34 M
What is Immuneering annual EBITDA year-on-year change?
Over the past year, IMRX annual earnings before interest, taxes, depreciation & amortization has changed by -$6.59 M (-12.81%)
What is Immuneering quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of IMRX is -$15.18 M
What is the all time high quarterly EBITDA for Immuneering?
Immuneering all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$3.22 M
What is Immuneering quarterly EBITDA year-on-year change?
Over the past year, IMRX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$50.30 K (+0.33%)
What is Immuneering TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of IMRX is -$73.81 M
What is the all time high TTM EBITDA for Immuneering?
Immuneering all-time high TTM earnings before interest, taxes, depreciation & amortization is -$3.22 M
What is Immuneering TTM EBITDA year-on-year change?
Over the past year, IMRX TTM earnings before interest, taxes, depreciation & amortization has changed by -$2.73 M (-3.84%)